CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0099 (clinicaltrials.gov NCT No: NCT01893320)
Title:A Phase I/II Study of Vosaroxin and Decitabine in Older Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Principal Investigator:Naval Daver
Treatment Agent:Decitabine; Vosaroxin
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
vosaroxin and decitabine can help to control AML or MDS. The safety of these
drugs will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Decitabine
Vosaroxin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Sunesis Pharmaceuticals, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naval Daver
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults